PHARMACOECONOMIC EVALUATION OF SELENASE AT NEWBORN BABIES IN CRITICAL CONDITION
https://doi.org/10.21886/2219-8075-2013-3-40-43
Abstract
Purpose: To reduce the economic costs of treatment of newborns in critical condition, using selenium, based on reducing the duration of carried out IVL and hospitalization.
Materials and methods: controlled randomized blinded clinical test of selenase infants with RDS and perinatal CNS, are on mechanical ventilation (mechanical ventilation) was carried out. 76 newborn children being in a critical condition were surveyed.
Randomization was carried out by a method of the computer program of a random number generator. In I group (n=36), except standard intensive therapy accepted in office (hospital), entered selenase in a dose of 10 mkg/kg/days intravenously slowly, within 10 days, II group (n=40) – group of control.
Results: during the test it was found and statistically proved that the group of children receiving selenase, duration of IVL and ongoing hospital stay was, respectively, 1.6 and 1.36 times less (p <0.05) than in the group of control.
Summary: the use of selenase at children with respiratory pathology helps to reduce the financial cost of treatment at 1.6 times and has pharmacoeconomic lucrative nature.
About the Authors
L. F. Dolotova
Rostov Research Institute of Obstetrics and Pediatrics
Russian Federation
43/38/2 Mechnikova st., Rostov-on-Don, 344012
Russian Federation
43/38/2 Mechnikova st., Rostov-on-Don, 344012
V. V. Estrin
Rostov Research Institute of Obstetrics and Pediatrics
Russian Federation
43/38/2 Mechnikova st., Rostov-on-Don, 344012
Russian Federation
43/38/2 Mechnikova st., Rostov-on-Don, 344012
References
1. Кассиль В.Л., Золотокрылина Е.С. Острый респираторный дистресс-синдром в свете современных представлений // Вестн. интенс. тер. – 2001. - № 31. – С. 9-14.
2. Чуканова Е.И. Фармакоэкономический анализ эффективности применения препарата Мидокалм® в сравнении с баклофеном и тизанидином у больных с дисциркуляторными энцефалопатиями // Русский медицинский журнал. - 2002. –Т. 10, № 12-13. – С. 75-85.
3. Norman R, Spencer A, Feder G. Cost-Effectiveness Analisis: What You Always Wanted to Know But Were Afraid to Ask. http://www. endabuse.org/health/ejournal/archive/1-5/cost_effective_analysis. php из кэша Google. (дата обращения 14.04.2013).
4. Ройтман Е.В. Инновации и экономика в современной клинической гемостазиологии.// Тромбоз, гемостаз и реология. - 2011. – № 3. - С. 66.
5. Heyland D.K., Dhaliwal R., Day A.G. et al. 2008. Critical Care Nutrition Group. Supplemental antioxidant nutrients: parenteral selenium. http://www.criticalcarenutrition.com/ docs/cpg/11.2_selenium_07.pdf. (дата обращения 12.04.2013).
Review
For citations:
Dolotova L.F., Estrin V.V. PHARMACOECONOMIC EVALUATION OF SELENASE AT NEWBORN BABIES IN CRITICAL CONDITION. Medical Herald of the South of Russia. 2013;(3):40-43. (In Russ.) https://doi.org/10.21886/2219-8075-2013-3-40-43
Views:
387
Email this article 